Thiazolidinediones and Metformin Associated with Improved Survival of Diabetic Prostate Cancer Patients

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2011 Mar 19

PMID 21415239

Citations 76

Authors

X-X He

S M Tu

M-H Lee

S-C J Yeung

Affiliations

Soon will be listed here.

Abstract

Background: The association between antidiabetic medications and the prognosis of human prostate cancer has not been explored. This study examined the impact of these drugs on the outcomes of diabetic patients with prostate cancer to provide a basis for diabetes management strategy in these patients.

Patients And Methods: Records of consecutive prostate cancer patients with coexisting diabetes mellitus type 2 who were treated at the study institution between 15 July 1999 and 31 December 2008 were reviewed. The survival, cancer pathological grade, stage at the time of diagnosis, and antidiabetic pharmacotherapy of the patients were analyzed.

Results: A total of 233 consecutive cases were analyzed. In Kaplan-Meier analysis, thiazolidinedione (log-rank, P = 0.005) and metformin (log-rank, P = 0.035) usage were significant predictors of improved overall survival, while insulin and insulin secretagogue usage were not significant predictors. Multivariate Cox regression analysis showed that thiazolidinedione {hazard ratio [HR] = 0.454 [95% confidence interval (CI) 0.213-0.965], P = 0.040} and metformin [HR = 0.550 (95% CI 0.315-0.960), P = 0.035] usage remained as significant predictors of favorable survival after controlling for variables including age, race, Gleason grade, and stage.

Conclusions: Thiazolidinediones and metformin appear to be associated with improved overall survival of diabetic prostate cancer patients. The choice of antidiabetic pharmacotherapy may influence overall survival of these patients.

Citing Articles

Thiazolidinedione derivatives: emerging role in cancer therapy.

Latambale G, Juvale K Mol Divers. 2025; .

PMID: 39899123 DOI: 10.1007/s11030-024-11093-3.

Hypoglycemic Agents Increase Regulatory Factor X1 to Inhibit Cancer Cell Behaviour in Human Glioblastoma Cells.

Shan W, Zuo K, Zuo Z J Cell Mol Med. 2024; 28(23):e70260.

PMID: 39636301 PMC: 11619449. DOI: 10.1111/jcmm.70260.

Thiazolidinedione derivatives in cancer therapy: exploring novel mechanisms, therapeutic potentials, and future horizons in oncology.

Ranjan G, Ranjan S, Sunita P, Pattanayak S Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39621087 DOI: 10.1007/s00210-024-03661-z.

Metformin: A Dual-Role Player in Cancer Treatment and Prevention.

Galal M, Al-Rimawi M, Hajeer A, Dahman H, Alouch S, Aljada A Int J Mol Sci. 2024; 25(7).

PMID: 38612893 PMC: 11012626. DOI: 10.3390/ijms25074083.

Overcoming Chemotherapy Resistance in Metastatic Cancer: A Comprehensive Review.

Eslami M, Memarsadeghi O, Davarpanah A, Arti A, Nayernia K, Behnam B Biomedicines. 2024; 12(1).

PMID: 38255288 PMC: 10812960. DOI: 10.3390/biomedicines12010183.

References

Xiang X, Saha A, Wen R, Ruderman N, Luo Z . AMP-activated protein kinase activators can inhibit the growth of prostate cancer cells by multiple mechanisms. Biochem Biophys Res Commun. 2004; 321(1):161-7. DOI: 10.1016/j.bbrc.2004.06.133. View

Shiau C, Yang C, Kulp S, Chen K, Chen C, Huang J . Thiazolidenediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xL/Bcl-2 functions independently of PPARgamma. Cancer Res. 2005; 65(4):1561-9. DOI: 10.1158/0008-5472.CAN-04-1677. View

Basaria S, Muller D, Carducci M, Egan J, Dobs A . Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy. Cancer. 2006; 106(3):581-8. DOI: 10.1002/cncr.21642. View

Wright J, Stanford J . Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control. 2009; 20(9):1617-22. PMC: 2767519. DOI: 10.1007/s10552-009-9407-y. View

Coker A, Sanderson M, Zheng W, Fadden M . Diabetes mellitus and prostate cancer risk among older men: population-based case-control study. Br J Cancer. 2004; 90(11):2171-5. PMC: 2410287. DOI: 10.1038/sj.bjc.6601857. View

Efferth T, Sauerbrey A, Steinbach D, Gebhart E, Drexler H, Miyachi H . Analysis of single nucleotide polymorphism C3435T of the multidrug resistance gene MDR1 in acute lymphoblastic leukemia. Int J Oncol. 2003; 23(2):509-17. View

Kasper J, Giovannucci E . A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2006; 15(11):2056-62. DOI: 10.1158/1055-9965.EPI-06-0410. View

Inaba M, Otani Y, Nishimura K, Takaha N, Okuyama A, Koga M . Marked hyperglycemia after androgen-deprivation therapy for prostate cancer and usefulness of pioglitazone for its treatment. Metabolism. 2004; 54(1):55-9. DOI: 10.1016/j.metabol.2004.07.010. View

Bowker S, Majumdar S, Veugelers P, Johnson J . Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29(2):254-8. DOI: 10.2337/diacare.29.02.06.dc05-1558. View

10.

Meyer T, Boerwinkle E, Morrison A, Volcik K, Sanderson M, Coker A . Diabetes genes and prostate cancer in the Atherosclerosis Risk in Communities study. Cancer Epidemiol Biomarkers Prev. 2010; 19(2):558-65. PMC: 2820124. DOI: 10.1158/1055-9965.EPI-09-0902. View

11.

Zhu K, Lee I, Sesso H, Buring J, Levine R, Gaziano J . History of diabetes mellitus and risk of prostate cancer in physicians. Am J Epidemiol. 2004; 159(10):978-82. DOI: 10.1093/aje/kwh139. View

12.

Hadad S, Fleming S, Thompson A . Targeting AMPK: a new therapeutic opportunity in breast cancer. Crit Rev Oncol Hematol. 2008; 67(1):1-7. DOI: 10.1016/j.critrevonc.2008.01.007. View

13.

Smith M, Lee H, Nathan D . Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006; 91(4):1305-8. DOI: 10.1210/jc.2005-2507. View

14.

DAmico A, Braccioforte M, Moran B, Chen M . Causes of death in men with prevalent diabetes and newly diagnosed high- versus favorable-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009; 77(5):1329-37. DOI: 10.1016/j.ijrobp.2009.06.051. View

15.

Snyder C, Stein K, Barone B, Peairs K, Yeh H, Derr R . Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis. 2010; 13(1):58-64. PMC: 3085982. DOI: 10.1038/pcan.2009.39. View

16.

Ribeiro D, Taboga S, Goes R . Diabetes induces stromal remodelling and increase in chondroitin sulphate proteoglycans of the rat ventral prostate. Int J Exp Pathol. 2009; 90(4):400-11. PMC: 2741150. DOI: 10.1111/j.1365-2613.2009.00657.x. View

17.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P . The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. DOI: 10.1038/sj.onc.1211024. View

18.

Koro C, Barrett S, Qizilbash N . Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf. 2006; 16(5):485-92. DOI: 10.1002/pds.1352. View

19.

Coughlin S, Calle E, Teras L, Petrelli J, Thun M . Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. Am J Epidemiol. 2004; 159(12):1160-7. DOI: 10.1093/aje/kwh161. View

20.

Hammarsten J, Hogstedt B . Hyperinsulinaemia: a prospective risk factor for lethal clinical prostate cancer. Eur J Cancer. 2005; 41(18):2887-95. DOI: 10.1016/j.ejca.2005.09.003. View